Hypertension affects nearly half of all Americans and more than one billion people worldwide. Hypertension, or high blood pressure, affects nearly half of all Americans and more than one billion ...
Recor Medical has crossed the FDA’s finish line with its renal denervation approach to tackling high blood pressure that hasn’t responded to medications or changes in a person’s lifestyle. It’s been a ...
Palo Alto, CA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced that the Centers for ...
ReCor Medical’s method for tackling stubbornly high blood pressure by targeting overactive nerves around the kidneys failed to meet its target in a clinical trial conducted in Japan and Korea—a ...
RONKONKOMA, N.Y., ReCor Medical, an emerging medical device company, disclosed today updated data for the REDUCE First-In-Man clinical study of its PARADISE (Percutaneous Renal Denervation System) ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announce the U.S. Food and Drug Administration ...
FRANKFURT, Germany—ReCor Medical, an emerging medical device company, announced today that its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation has ...
PALO ALTO, Calif.--(BUSINESS WIRE)--ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the appointment of Lara Barghout ...
ReCor Medical, Inc. (“ReCor”) and Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings Co., Ltd., today announced that the RADIANCE II US FDA IDE pivotal trial evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results